Compare two forms and doses of vonafexor and see if the high dose interacts with other drugs
Official title: A Phase 1, Two Parts, Open-label, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) in Healthy Volunteers and Evaluation of Potential Drug-Drug Interactions
Run by Enyo Pharma · NCT07251153 · Data updated 2026-11-12
This test looks at how two doses and two formulations of vonafexor (EYP651 and vonafexor acid) are absorbed and processed in healthy adults and whether the high dose interacts with common medicines.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Enyo Pharma Industry-sponsored |
| Locations | 1 site (Gières) |
| Status | Recruiting |
| Started | October 28, 2025 |
| Main results expected | December 18, 2025 |
| Study ends | October 28, 2026 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07251153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18–65 with BMI 18–30, normal clinical exam, ECG and lab results, non- or light-smokers, and women willing to use effective contraception or who are non-childbearing.
✕Probably not a fit
People with active medical conditions, pregnant or breastfeeding women, those outside the 18–65 range, or those taking multiple chronic medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an open-label Phase 1 program with two parts: Part A is a randomized two-period crossover comparing PK and PD of two dose levels and formulations (EYP651 versus vonafexor acid), and Part B is a three-period parallel-arm design testing drug–drug interactions with the high EYP651 dose. Healthy men and women aged 18–65 with BMI 18–30, normal labs, ECG, and vital signs will be enrolled under strict contraception and smoking criteria. Part A lasts about 8 weeks per participant and Part B about 12 weeks per participant. Interventions include low and high doses of EYP651/vonafexor and coadministration with a CYP3A4 inhibitor, a transporter substrate, and CYP2C8/CYP2C9 substrates to probe interaction pathways.
Why it matters
Potential benefit: If successful, the results could clarify safe dosing and co-prescription guidance by showing formulation differences and any clinically important drug interactions.
How similar studies have gone: Early-phase pharmacokinetic and drug–drug interaction studies of vonafexor formulations have been performed previously, so the approach is standard though specific interaction results vary by formulation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy male or female subject, aged 18-65 years inclusive. * Females of childbearing potential: commitment to use a highly effective method of birth control which result in a low failure rate. Females of non-childbearing potential: either at least 3 months surgically sterilized or at least 1-year postmenopausal confirmed by the follicle stimulating hormone (FSH) level. Males: commitment to use an adequate contraceptive method consistently and correctly. * Negative pregnancy test for childbearing potential women or FSH ≥ 40 IU/mL for postmenopausal women. * Non-smoker subject or smoker of maximum 5 cigarettes a day and able to stop during the study. * Body Mass Index (BMI) between 18 and 30 kg/m2 inclusive. * Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination). * Normal Blood Pressure and Heart Rate. * Normal ECG recording on a 12-lead ECG. * Laboratory parameters within the normal range of the laboratory (hematology, hemostasis, blood chemistry tests, urinalysis). * Normal dietary habits. * Signing a written informed consent prior to selection. * Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research. Exclusion Criteria: * Any relevant history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic or infectious disease. * Frequent headaches and / or migraine, recurrent nausea and / or vomiting. * Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension. * Blood donation in the 2 months before administration. * General anaesthesia in the 3 months before administration. * Presence or history of drug allergic condition and/or hypersensitivity. * Inability to abstain from intense muscular effort. * Any drug intake (except paracetamol and contraceptives) during the month prior to the first administration. * History or presence of drug or alcohol abuse (alcohol consumption \> 40 grams / day). * Excessive consumption of beverages with xanthine bases (\> 4 cups or glasses / day). * Positive Hepatitis B surface antigen or anti Hepatitis C Virus antibody, or positive results for Human Immunodeficiency Virus 1 or 2 tests. * Positive results for drugs of abuse tests. * No possibility of contact subject in case of emergency. * Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. * Exclusion period of a previous study. * Administrative or legal supervision. * Subject who would receive more than 6'000 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Where it's running
-
Eurofins Optimed
Gières, France Recruiting
Study contacts
- Study coordinator: Clinical project manager
- Email: mod@enyopharma.com
- Phone: +33 (0)4 37 70 02 19
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of Exercise Snacks on Muscle Size and Strength in Healthy Young Adults
This study tests whether many small workouts throughout the week can build muscle size and improve strength in healthy, untrained young adults compared with the usual twice-weekly workouts.
-
ORX489 safety and dosing in healthy adults ages 18 to 60
This will test whether ORX489 tablets are safe, well tolerated, and how they are processed in the body in healthy men and women aged 18 to 60.
-
ReHIIT Prehabilitation in Healthy Adults
This pilot tests a combined resistance and high‑intensity interval training program to establish baseline physiology in healthy adults before applying findings to cancer patients.
-
Safety and drug levels of a 3‑month naltrexone implant (BICX104) with or without bupropion versus monthly Vivitrol injections
This will test whether a three‑month naltrexone implant (BICX104), given alone or with extended‑release bupropion, is safe and keeps steady drug levels compared with monthly Vivitrol injections in healthy adults.
-
Low-frequency vibrating mat for sleep and daily stress recovery
This test will see if using a low-frequency vibrating mat at home for three weeks improves stress recovery, sleep quality, mood, and attention in healthy adults aged 18-45.
-
Comparison of two 10 mg torasemide tablet formulations in healthy adults under fasting conditions
We will test whether a Berlin-Chemie 10 mg torasemide tablet works the same as Unat® 10 mg in healthy adults after fasting.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.